Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03893955 · ClinicalTrials.gov registry record · Phase 1

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

A Phase 1 study of Cancer and Advanced Solid Tumors, sponsored by AbbVie.

Active
Registry status
Phase 1
Development phase
150
Enrollment target
20
Study locations

NCT03893955 is a Phase 1 study of Cancer and Advanced Solid Tumors that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 150 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 17 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03893955, a Phase 1 study of Cancer and Advanced Solid Tumors, is active but no longer recruiting, sponsored by AbbVie.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
150 participants
Enrollment target
20
Study locations

Study Summary

A study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or chemotherapy in participants with selected solid tumors. This study consists of 2 main parts, a dose-escalation phase and a dose-expansion phase. The dose-expansion phase can begin once the recommended phase 2 dose/maximum tolerated dose (RP2D/MTD) is determined in the dose-escalation phase.

Conditions Studied

Cancer Advanced Solid Tumors Non-small Cell Lung Cancer (NSCLC) Metastatic Solid Tumors Triple Negative Breast Cancer (TNBC)

Interventions

  • DRUG Carboplatin
  • DRUG Nab-paclitaxel
  • DRUG ABBV-927
  • DRUG ABBV-181
  • DRUG ABBV-368

Study Locations (20)

North Carolina

  • Duke Cancer Center /ID# 217641 - Durham
  • Carolina BioOncology Institute /ID# 210664 - Huntersville

Texas

  • Mary Crowley Cancer Research /ID# 210716 - Dallas
  • NEXT Oncology /ID# 210717 - San Antonio

Other

  • Centre Jean Perrin /ID# 217911 - Clermont-Ferrand
  • AP-HP - Hopital Bichat - Claude-Bernard /ID# 212869 - Paris

Arkansas

  • Highlands Oncology Group, PA /ID# 218863 - Springdale

California

  • St Jude Hospital dba St Joseph /ID# 211130 - Santa Rosa

Connecticut

  • Yale University School of Medicine /ID# 210678 - New Haven

Florida

  • Moffitt Cancer Center /ID# 215037 - Tampa

Indiana

  • Fort Wayne Medical Oncology and Hematology, Inc /ID# 226072 - Fort Wayne

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2019-05-21
Est. Completion 2026-03
Phase Phase 1

Sponsor

AbbVie

526 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03893955

The ClinicalTrials.gov registry entry for NCT03893955 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (96% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.

NCT03893955 reports 20 study locations spanning 17 distinct geographic areas - top geographies include North Carolina, Texas, Other.

Frequently Asked Questions

What is clinical trial NCT03893955 about?

NCT03893955 is a clinical study titled "A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors". A study evaluating the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-927 with ABBV-368, Budigalimab (ABBV-181) and/or chemotherapy in participants with selected solid tumors. This study consists of 2 main parts, a dose-escalation phase and a dose-expansion phase. ...

What is the current status of trial NCT03893955?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2019-05-21. Estimated completion is 2026-03.

What conditions does trial NCT03893955 study?

This clinical trial studies the following conditions: Cancer, Advanced Solid Tumors, Non-small Cell Lung Cancer (NSCLC), Metastatic Solid Tumors, Triple Negative Breast Cancer (TNBC).

What interventions are being tested in trial NCT03893955?

The interventions under investigation include: Carboplatin (DRUG), Nab-paclitaxel (DRUG), ABBV-927 (DRUG), ABBV-181 (DRUG), ABBV-368 (DRUG).

Who is sponsoring clinical trial NCT03893955?

This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03893955 being conducted?

This trial has 20 study locations across Arkansas, California, Connecticut, Florida, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cancer

All registered trials for this condition

Advanced Solid Tumors

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.